Current Report Filing (8-k)
June 17 2016 - 9:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) June 16, 2016
MEDIFIRST
SOLUTIONS, INC
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55465
|
|
27-3888260
|
(State
or other
jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
incorporation)
|
|
|
|
Identification
No.)
|
4400
Route 9 South, Suite 1000, Freehold, NJ
|
|
07728
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (732)-786-8044
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01
|
Regulation
FD Disclosure
|
On
June 16, 2016, Medifirst Solutions, Inc. (the “Company”) issued a press release updating shareholders on the progress
of the Company’s Premarket Notification 510(k) submission to the U.S. Food and Drug Administration for the Company’s
“The Time Machine” Series Laser and its successful completion of testing for IEC 60601-1-2 Medical Electrical Equipment
Part 1-2: General Requirements for Safety: Electromagnetic Compatibility on its Time Machine TTML-8102000 Laser Thermal Therapeutic
Device.
A
copy of the press release is attached herewith as Exhibit 99.1.
The
information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall
not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated June 16, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
MEDIFIRST
SOLUTIONS, INC.
|
|
|
Dated:
June 16, 2016
|
By:
|
/s/
Bruce Schoengood
|
|
|
Bruce
Schoengood
President
and Chief Executive Officer
|
3